Corpus ID: 17811979

Long term follow-up of Thalidomide plus Interleukin-2 based therapy in metastatic renal cell cancer patients Research

@inproceedings{Amato2009LongTF,
  title={Long term follow-up of Thalidomide plus Interleukin-2 based therapy in metastatic renal cell cancer patients Research},
  author={R. Amato and M. Khan and Somyata Saxena},
  year={2009}
}
__________________________________________________________________________________ *Correspondence: Robert J Amato, DO, Professor, University of Texas Medical School, Department of Internal Medicine, Division of Oncology, 6410 Fannin, Suite 710, Houston, Texas 77030, USA; Tel: 832-325-7701; Fax; 713-512-7132; e-mail: Robert.Amato@uth.tmc.edu 

Figures and Tables from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
  • 4,346
  • PDF
Rising incidence of renal cell cancer in the United States.
  • 1,447
  • Highly Influential
  • PDF
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
  • 821
  • PDF
Thalidomide is an inhibitor of angiogenesis.
  • 1,304
  • Highly Influential